INTRODUCTION
The incidence of prostate cancer is increasing in industrialized countries, where it is the third most frequently diagnosed malignancy in males. 1, 2 in the US, prostatic malignancy is the most frequent male cancer and the second leading cause of death from cancer in men. 3 Besides malignancy, benign hyperplasia of the prostate is also common in elderly males, affecting the majority of males past the age of 80. 2 Although the aetiology and pathogenesis of prostate cancer is not as yet known, 1, 2 there is evidence that there is a genetic basis to the disease. For example, there is evidence for the existence of a hereditary variant of prostate cancer, characterized by an onset early in age, aggressive nature and insensitivity to environmental influence. 1, 2 Moreover, a number of tumor suppressor genes (e.g. P53, APC, MCC, DCC, BRCA1, WAF1/CIP1) and associated chromosomal regions (i.e. 6p12-24 and 17q21) have recently been implicated in human prostate cancer. 4 On the other hand, various epidemiological and casecontrolled studies have shown a positive relation between dietary fat intake and prostate cancer. [5] [6] [7] not only the amount of fat but also, perhaps even more importantly so, the quality of fat appears to relate to prostate cancer risk. Various population studies have indicated an increased prostate cancer risk with increasing animal and saturated fat intake. 1, 8 There are indications that intake of n6 polyunsaturated fatty acids (PUFA) may promote, while n3 PUFA may protect from or inhibit, prostatic cancerogenesis. 9 ,11 moreover, it is possible that the ratio n3/n6
PUFA may be implicated in prostate cancer. 11, 12 There are indications that dietary intake of linoleic acid (C18:2), an essential PUFA of the n6 family, may be associated with increased risk for prostate cancer. 13 some studies have suggested that linoleic acid and its immediate and intermediate metabolites may stimulate prostate tumor growth. 14, 15 for example, arachidonic acid (C20:4), a linoleic acid-desaturated metabolite, has been reported to stimulate prostate tumor growth 16 and to protect prostate carcinoma cells from apoptosis. 17 Arachidonic acid is metabolized via the cyclooxygenase, lipoxygenase, and cytochrome P450-dependent monooxygenase pathway. 18 lipoxygenase arachidonic acid-derived metabolites have been implicated in various stages of the carcinogenic process such as tumor growth and proliferation, 16, 19, 20 vascularization and angiogenesis, 21 cancer cell motility and interaction with platelets and vasculature, and invasiveness. 3, 18, 22 In addition to lipoxygenase, there are indications that cyclooxygenase arachidonic acid-derived metabolites may be implicated in prostate tumor growth and metastases. [23] [24] [25] On the other hand, it has been reported that marine oil fatty acids such as eicosapentaenoic (C20:5) and docosahexaenoic (C22:6) acids may inhibit prostate cancer cell growth via inhibiting lipoxygenase and cyclooxygenase products of arachidonic acid metabolism. 26 One objective of the present study was to study adipose tissue fatty acid composition, a measure of long-term (1-3 year) or habitual dietary fat intake, 27, 28 in prostate cancer vs benign hyperplasia patients. Another objective of the present investigation was to study whether prostatic tissue fatty acid synthesis differentiates between these two groups of patients. Finally, the present investigation aimed at exploring the extent to which prostatic tissue fatty acid composition relates to the manifestation of extraprostatic disease including possible metastasis.
SUBJECTS AND METHODS

Subjects
The subjects were 71 male patients from the island of Crete. Half the patients (n=35) had been diagnosed with benign hyperplasia of the prostate, half with prostatic malignancy (n=36). Patients were examined at the outpatient clinic, urology unit, University Hospital, University of Crete. Prostate cancer diagnosis was performed with digital rectal examination, measurement of serum prostate specific antigen, transrectal ultrasound and prostate biopsy. Benign prostatic hyperplasia was diagnosed on the basis of medical history, digital rectal examination and transrectal ultrasound. Both groups of patients were operated approximately 10 days after diagnosis. Operative sample specimens were histologically examined at the pathoanatomic laboratory. Surgical operations and post-operative follow-ups were performed by the same physicians that had made initial examinations and diagnoses. The study took place between October 1997 and September 1999.
Sample preparation and analysis of prostatic tissue fatty acids
Prostate gland samples were kept frozen at À801C. Prior to analysis the samples were thawed, cut in small pieces by means of a scalpel on a glass surface and a portion of about 0.5 g was transferred to l0 ml screw-capped vials. Two milliliters of 0.5 M NaOH in methanol was added and the sample was homogenized for 5 min with an ultraturax homogenizer.
Methyl esters of the fat component fatty acids (FAME) were prepared in the screw-capped vials according to the method described by Metcalfe et al. 29 Briefly, the sample fat was saponified with the homogenizing solution (NaOH in methanol) and the FAME were prepared with 14% boron trifluoride in methanol. The FAME were then extracted with hexane containing BHT (0.010% w/v) after washing with saturated NaCl. The hexane (upper layer) containing the FAME was transferred to GC vials and stored at À201C until analysis. The FAME were separated on a 50 m Â 0.22 mm BPX 70 capillary column, coated with a 0.25 mm film of cyanopropyl silicone provided by SGE (Melbourne, Australia), using an Agilent Technologies (former Hewlett-Packard HP, Avondale, PA, USA) HP 6890 gas chromatograph equipped with an MSD-5972 mass ionization detector. The HP MS Chemstation software was used for quantitation and identification of peaks. The identification of over 50 FAME Peaks was accomplished by means of mixed FAME standards purchase from Sigma (St Louis, MO, USA) and by reference to mass spectra library. The analytical conditions employed were as follows: volume injected 1 ml, carrier gas helium (1.0 ml/min), injector temperature 2301C, MSD transfer line 2801C, split ratio 1:20 to 1:50, and oven temperature from 1201C to 2451C with stepped temperature program. These conditions resulted in a total run time of 40 min.
Adipose tissue measures
The fatty acid profile of adipose tissue at one site reflects composition at other sites. 30 Nevertheless, samples were taken from the same site in all subjects, namely, the left upper outer quadrant of the gluteal area. Adipose tissue samples were stored in À801C. Prior to analysis samples were thawed and about 50 mg of fat was transferred to 10 ml screw-capped tubes with the help of Pasteur pipettes and several drops (B0.5 ml) of Chloroform: methanol (2:1 v/v). The fatty acid estimation method used was the same as that of the previous section.
RESULTS
There were 35 men with benign hyperplasia and 36 men with prostate cancer. The former group had a mean age of 68 years and a standard deviation of 12 years, while these values for the latter group were 69 and 9 years, respectively. The difference in age between the two different groups was not statistically significant. Table 3 depicts means and standard deviations of prostatic tissue fatty acids in prostate hyperplasia vs prostatic-confined cancer vs extraprostatic disease including possible metastasis. ANOVA and post hoc comparisons confirmed most of the above findings. However, there were no significant differences between the prostate-confined cancer group and the extraprostatic cancer group in any of the variables.
Within the prostate cancer group there were significant correlations between prostatic tissue C18:0 and C18:1 n9 (r = À0.96, Po0.0005) and between prostate tissue saturated and monounsaturated fatty acids (r = À0.96, Po0.0005).
DISCUSSION
Only a limited number of human studies have implemented biomarkers of dietary fatty acid intake in prostate cancer. 31, 32 The present study has investigated the role of adipose tissue fatty acid composition, a biomarker of long-term (1-3 year) or habitual dietary fat intake, 27 The significantly increased monounsaturated and oleic acid levels in the benign hyperplasia as opposed to the prostate cancer group probably stems from a correspondingly increased dietary intake of olive oil, the main dietary source of monounsaturated fat in the island of Crete. However, given that levels of olive oil ingredients such as alpha-tocopherol, squalene and polyphenols have not been assessed in the present study, it is not known whether in addition to oleic acid these ingredients are also elevated in the benign hyperplasia as opposed to the prostate cancer patients. The effect of squalene and naturally occurring polyphenolic compounds on prostate cancer has not yet been studied. Whether biomarkers of these ingredients differentiate prostatic hyperplasia from prostatic cancer is not known. The extent to which these compounds confer protection against prostate cancer is a subject open to investigation.
A main finding of the present study was a significantly decreased prostate tissue sum saturated fatty acids and an elevated sum monounsaturated fatty acids in cancer as opposed to benign hyperplasia patients. This finding cannot be discussed in relation to findings of other investigations given a lack of similar studies in prostate cancer and hyperplasia patients. Nevertheless, it has been reported that on a cellular level, the ratio of saturated to monounsaturated fatty acids or saturation index (SI) is determined by stearoyl-CoA or delta-9 desaturase, the rate-limiting enzyme in the monounsaturated fatty acids synthesis from saturated fatty acids. 64 Cell membrane fluidity has been reported to depend, among other things, on the lipid composition of cellular membranes or a proper balance of saturated and monounsaturated fatty acids. 64 Some studies have suggested that a decreased SI or reduced stearic to oleic acid ratio is associated with increased tumor cell fluidity and malignant transformation . 65 The stearic to oleic acid ratio has been reported to be reduced in a number of cancers and has often been used as a marker of malignancy. 66 The significantly decreased prostate tissue stearic (C18:0) to oleic acid (C18:1) ratio in cancer as opposed to benign hyperplasia patients in the present study (Table 3) agrees with findings of other prostate cancer studies. Along the same lines, the significantly reduced prostate tissue sum saturated to monounsaturated fatty acids ratio (M/S ratio) in cancer as opposed to benign hyperplasia patients in the present study (Table 3) supports findings of other studies implicating low SI with malignancy. Given that the cancer patient group had significantly higher adipose stearic acid than the benign hyperplasia group (Table 1) , the decreased prostate tissue stearic acid levels in the former as opposed to the latter group cannot stem from reduced dietary intake in the particular fatty acid. Rather, the lower prostate tissue stearic acid levels have probably resulted from enhanced stearoyl-CoA or delta-9 desaturase activity and associated biosynthesis of oleic from stearic acid in cancer as opposed to benign hyperplasia patients. This is supported by the very high correlation (r = À0.96) between prostatic tissue stearic and oleic acid levels in the cancer patient group. In addition, the magnitude of this correlation appears to indicate that the decreased stearic acid levels in cancer as opposed to hyperplasia patients may reflect increased delta-9 desaturase activity and oleic acid biosynthesis rather than increased metabolism of stearic acid in neoplasia-related processes. Also, the fact that longer chain saturated prostatic tissue fatty acids are decreased rather than increased in cancer as opposed to hyperplasia patients seems to indicate that the lower stearic acid levels in the former group have not resulted from increased utilization of this fatty acid for the formation of longer-chain derivatives (Table 3) . Nevertheless, some reports have indicated that stearic acid is cytotoxic to tumor cells, 67 inhibits mitogenesis 68 and tumor proliferation and development 69, 70 and metastasis. 71 Although only a very limited number of studies have explored the role of stearic acid in cancer, the significantly elevated prostatic tissue stearic acid levels in our hyperplasia as opposed to our cancer patients seem to support the reported inhibiting role of this fatty acid in malignancy. The most pronounced difference between benign hyperplasia and prostate cancer patients, in the present study, has been a 3-fold elevation in prostate tissue palmitoleic acid (C16:1 n9) levels in the latter patients (Tables 2 and 3) (Fig. 1) . It has been reported that increases in serum phospholipid palmitoleic acid levels are associated with elevated prostate cancer risk. 72 Furthermore, elevations in palmitoleic acid levels appear to be associated with some cancers. [73] [74] [75] Palmitoleic acid has been reported to be an inducer of leukemic cell differentiation 76 and an inhibitor of Ehrlich ascite tumor cell shrinkage. 77 In addition, elevated palmitoleic acid 75 Finally, elevated membrane phospholipid palmitoleic acid levels have been observed in breast tumors with poor histoprognostic grade. 78 The significant and pronounced elevations in prostatic tissue palmitoleic acid levels in cancer as opposed to hyperplasia patients in the present study, therefore, support findings linking palmitoleic acid elevations with cancer. Given that the cancer patient group and the benign hyperplasia group did not differ significantly in adipose arachidonic acid levels (Table 1) , the decreased prostate tissue arachidonic acid levels in the former group (Tables   2 and 3) (Fig. 2) cannot stem from reduced dietary intake in the particular fatty acid relative to the latter group. Also, the fact that the cancer group had significantly higher prostatic tissue linoleic acid levels than the hyperplasia group indicates that the lower prostatic tissue arachidonic acid levels in the former group have not resulted from insufficient fatty acid precursors in this group. However, it is not certain whether this decrease in prostatic tissue arachidonic acid levels in the cancer as opposed to the hyperplasia group is due to lower activity of delta-5 and delta-6 desaturases, the enzymes responsible for the formation of arachidonic acid from its precursor linoleic acid. Even though the cancer group There were no significant differences between the two prostate cancer groups in any of the variables studied. *Denotes a significant difference with the benign hyperplasia group as the reference category (Po0.05, two-tailed ANOVA and post hoc comparisons).
appeared to have significantly lower delta-5 and delta-6 desaturases or C20:4 n6/C18:2 n6 ratios than the hyperplasia group, the fact that the two groups did not differ significantly in C20:5 n3/C18:3 n3 ratios (Table 2) , another index of delta-5 and delta-6 desaturases, raises questions as to whether these desaturases have been responsible for the observed decrement in arachidonic acid levels in the former group. Nevertheless, given that arachidonic acid is metabolized to adrenic acid (C22:4 n6) and subsequently desaturated to docosapentaenoic acid (C22:5 n6), 79 the fact that the cancer group had significantly decreased docosapentaenoic acid than the hyperplasia group indicates that the lower arachidonic acid levels in the former group have not resulted from Prostate cancer vs hyperplasia 473 increased arachidonic acid utilization and biosynthesis of longer-chain fatty acid derivatives. Similar to the findings of the present study, other studies have also reported decreased prostate phospholipid arachidonic acid levels in prostatic cancer as opposed to benign prostatic disease. 2, 79, 80 Furthermore, it has been observed that prostate cancer cell lines with a higher metastatic potential have lower phospholipid arachidonic acid levels than those with lower metastatic potential. 81, 82 epidermal growth factor (EGF) has been implicated in both androgen-dependent and androgen-independent prostate cancer. 83, 84 EGF has been reported to stimulate PLA2 and arachidonic acid release from membrane phospholipids, and EGF-induced mitogenesis has been reported to be contingent upon arachidonic acid release. 16, 17 Once released, arachidonic acid can be metabolized through cyclooxygenase, lipoxygenase, and cytochrome P450-dependent monooxygenase pathway. 18 One likely explanation for the observed significant decrement in prostatic tissue arachidonic acid levels in cancer as opposed to the benign hyperplasia group is an associated enhanced utilization and metabolism of arachidonic acid via the cyclooxygenase and lipoxygenase pathways. 2, 79 Micromolar concentrations of arachidonic acid have been reported to stimulate human prostate cancer cell growth in vitro. 16 Prostate cancer cells fed with arachidonic acid showed a pronounced increase in eicosatetraenoid metabolites of 5-lipoxygenase (5-HETEs). AA861 and MK886, inhibitors of 5-lipoxygenase, inhibited the growth stimulatory effect of arachidonic acid. Addition of 5-HETEs reversed the growth inhibitory effect of MK886 and exhibited a growth stimulatory effect similar to that of arachidonic acid. 16 In another study, arachidonic acid has been reported to stimulate prostate cancer cell proliferation through the production of 5-hydroxyeicosatetraenoic acid (5-HETE), an arachidonic acid 5-lipoxygenasederived metabolite. 19 Inhibition of 5-lipoxygenase by MK886 completely blocked 5-HETE production and induced massive and rapid apoptotic death in both hormone-responsive (LNCaP) and unresponsive (PC-3) human prostate cancer cell lines. 19 Addition of exogenous 5-HETE protected prostate cancer cells from the apoptosis induced by MK886. These findings suggested that 5-HETE is a potent survival factor for human prostate cancer cells. 8, 19 The proliferative and anti-apoptotic effect of 5-lipoxygenase on prostate cancer cells was also shown in another study. Not only lipoxygenase but also cyclooxygenase arachidonic acid-derived metabolites may be implicated in prostate tumor growth and metastases. It has been reported that the production of prostaglandin E-2 (PGE 2 ), a cyclooxygenase metabolite, from arachidonic acid was 10-fold higher in prostate cancer tissue than in benign prostatic tissue. 79 PGE 2 has been reported to stimulate prostatic tumor growth 23 and to possibly predict prostate cancer cell metastatic potential. 24 Moreover, inhibition of cyclooxygenase-2 by NS398, a selective cyclooxygenase-2 inhibitor, induced time-and dosedependent apoptosis in a human prostate cancer cell line. 25 The cyclooxygenase inhibition and resulting apoptosis was associated with a down-regulation in expression of bcl-2 oncogene, an inhibitor of apoptosis. 25 In another study, inhibition of cyclooxygenase and cyclooxygenase-2 was associated with inhibition of invasiveness in DU-145 and PC-3 human prostate cancer cell lines. Addition of PGE 2 reversed the inhibition of invasiveness by NS398, a selective cyclooxygenase-2 inhibitor. The authors commented on the potential use of cyclooxygenase-2 inhibitors as chemopreventive and therapeutic agents of prostate cancer invasion. 85 Finally, there are indications that PGE 2 may have immunosuppressive effects. 86 It is possible, therefore, that one reason for the observed significant decrement in prostatic tissue arachidonic acid levels in cancer as opposed to the benign hyperplasia group, in the present study, may be an associated enhanced utilization and metabolism of arachidonic acid via the cyclooxygenase 16, 19 and, perhaps even more importantly so, lipoxygenase pathways.
2,79
Unlike linoleic and arachidonic acids, there are indications that marine oil fatty acids such as eicosapentaenoic (C20:5) and docosahexaenoic (C22:6) acids, long-chain essential PUFA of the omega-3 family, may inhibit prostate cancer cell growth, 14 This effect may be due to a possible inhibition of both lipoxygenase and cyclooxygenase products of arachidonic acid metabolism by omega-3 PUFA. 26 Although the two patient groups did not differ significantly in adipose docosahexaenoic acid levels, the significantly increased prostatic tissue docosahexaenoic acid levels in the benign hyperplasia as opposed to prostate cancer patients, in the present study, appear to confer support to the reported protective effect of docosahexaenoic acid in prostatic neoplasia (Tables 1-3). 14,32
Generally, omega-6 PUFA have been reported to promote, whereas omega-3 PUFA have been reported to inhibit, prostate cancer cell growth. 9, 12, 14, 87 One study reported that compared to benign hyperplasia and control subjects, prostate cancer patients had lower serum omega-3/omega-6 PUFA ratios. 11 In another study, prostate cancer patients with a poor histopathological status were found to have 1.5-3.3-fold lower prostatic omega-3/omega-6 fatty acid ratios than patients with a more favorable histopathological status. 88 Such observations have led to the suggestion that the ratio of omega-3/ omega-6 PUFA should be increased in the diets of groups at high risk for prostate cancer. 12 The significantly decreased omega-3/omega-6 PUFA ratio in the prostate cancer patient as opposed to the benign hyperplasia group in the present study, therefore, appears to confirm findings linking reduced omega-3/omega-6 PUFA ratios with prostate cancer (Tables 2 and 3 ).
In conclusion, the elevated adipose tissue saturated and reduced monounsaturated fatty acids in cancer as opposed to benign hyperplasia patients supports findings linking increased dietary saturated and reduced monounsaturated fat with prostate cancer risk. Whether the elevated adipose oleic acid in hyperplasia as opposed to prostate cancer patients reflects also elevated levels of olive oil-derived squalene, alpha-tocopherol and polyphenols is not known. The reduced prostatic tissue stearic to oleic acid ratio in cancer as opposed to hyperplasia patients supports the reported utility of the particular ratio as a malignancy index. The relation between reduced prostatic tissue stearic to oleic acid ratio and prostate cancer may be mediated by increases in tumor cell fluidity. The lower prostatic tissue stearic acid levels in cancer as opposed to hyperplasia patients appear to confer support to the reported inhibiting role of this fatty acid in malignancy. On the other hand, the 3-fold elevated prostatic tissue palmitoleic acid in the cancer as opposed to the benign hyperplasia group supports the reported cancer-promoting effects of this fatty acid. The reduced prostatic tissue arachidonic acid levels in cancer as opposed to hyperplasia patients support findings of other studies. The particular decrease possibly stems from an enhanced metabolism of arachidonic acid via lipoxygenase and cyclooxygenase pathways, and the formation of derivatives such as 5-HETE, 15-HETE, 12(S)-HETE and PGE 2 . The significantly increased prostatic tissue docosahexaenoic acid in the hyperplasia group as opposed to the cancer group appears to confer support to the reported protective effect of docosahexaenoic acid in prostatic cancer. Finally, the significantly reduced omega-3/omega-6 PUFA ratio in the prostate cancer patient as opposed to the benign hyperplasia group appears to confirm findings linking reduced omega-3/ omega-6 PUFA ratios with prostatic cancer.
